- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00309283
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study (ALADIN)
Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary renal disease, responsible for 8% to 10% of the cases of end stage renal disease (ESRD) in Western countries. At comparable levels of blood pressure control and proteinuria, patients with ADPKD have faster decline in glomerular filtration rate than those with other renal diseases and do not seem to benefit to the same extent of ACE inhibitor therapy. A reasonable explanation for the above findings is that in ADPKD progression is largely dependent on the development and growth of cysts and secondary disruption of normal tissue. Thus, renoprotective interventions in ADPKD - in addition to achieve maximal reduction of arterial blood pressure and proteinuria and to limit the effects of additional potential promoters of disease progression such as dyslipidemia, chronic hyperglycemia or smoking - should also be specifically aimed to correct the dysregulation of epithelial cell growth, secretion, and matrix interactions characteristic of the disease.
Evidence that specific receptors for somatostatin are present in the kidney tissue, arises the possibility that somatostatin treatment in patients with ADPKD might inhibit fluid formation and eventually induce the shrinking of renal cysts.To evaluate the tolerability and the safety of long-acting somatostatin in ADPKD patients, a prospective cross-over controlled study has been recently performed. This pilot study demonstrated the safety of six month treatment of long-acting somatostatin in patients with ADPKD. Moreover, the percent increase of total kidney volume was significantly lower in patients on somatostatin than in placebo. Overall, these findings provide the basis for designing a long-term study in ADPKD patients aimed to document the efficacy of the somatostatin treatment in preventing further increase or even reducing the total kidney volume and the renal volume taken up by small cysts, eventually halting kidney disease progression.
Study Overview
Status
Intervention / Treatment
Detailed Description
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary renal disease, responsible for 8% to 10% of the cases of end stage renal disease (ESRD) in Western countries.
At comparable levels of blood pressure control and proteinuria, patients with ADPKD have faster decline in glomerular filtration rate (GFR) than those with other renal diseases and do not seem to benefit to the same extent of ACE inhibitor therapy. A reasonable explanation for the above findings is that in ADPKD progression is largely dependent on the development and growth of cysts and secondary disruption of normal tissue. Thus, renoprotective interventions in ADPKD - in addition to achieve maximal reduction of arterial blood pressure and proteinuria and to limit the effects of additional potential promoters of disease progression such as dyslipidemia, chronic hyperglycemia or smoking - should also be specifically aimed to correct the dysregulation of epithelial cell growth, secretion, and matrix interactions characteristic of the disease.
The fluid filling renal cysts in human polycystic kidney is formed mainly by a secretion process of the tubular epithelium lining the cysts. Secretion and re-absorption take place at approximately the same rate, with secretion slightly higher, so that the amount of fluid in the cysts increases slowly over time. The same process, via the secondary active chloride transport, is also involved in the secretion of fluid into the lumen of proximal tubules in teleost and elasmobranch fishes. Of interest, this process of chloride transport can be markedly inhibited by somatostatin, as demonstrated in the shark rectal gland.
Recently, somatostatin analogues have become available and used with negligible side effects for long-term treatment of tumors (up to 8-12 months). To evaluate the tolerability and the safety of long-acting somatostatin in ADPKD patients, a prospective cross-over controlled study has been recently performed. This pilot study demonstrated the safety of six month treatment of long-acting somatostatin in patients with ADPKD. Moreover, the percent increase of total kidney volume was significantly lower in patients on somatostatin than in placebo. Preliminary data on late stage ADPKD also suggest that loss of renal function in these patients closely correlates with the increase in kidney volume taken by small cysts (<5 mm3), but not total cyst volume.
Overall, these findings provide the basis for designing a long-term study in ADPKD patients aimed to document the efficacy of the somatostatin treatment in preventing further increase or even reducing the total kidney volume and the renal volume taken up by small cysts, eventually halting kidney disease progression.
Aims
The general aim of the study is to compare the effects on disease progression of three year treatment with long-acting somatostatin or placebo in patients with ADPKD and normal renal function or mild to moderate renal insufficiency. Specifically, the following aims will be pursued:
Primary To compare in somatostatin and placebo ADPKD groups the change over baseline of the total kidney volume at 1 and 3 years follow-up (estimated by gadolinium contrast enhanced and T2-weighted magnetic resonance imaging, MRI).
Secondary
As secondary efficacy endpoints, the following parameters (absolute and percent change over baseline by MRI analysis) will be compared in the two ADPKD groups at baseline, at 1 and 3 years follow-up:
- Renal cyst volume
- Total renal parenchymal volume
- Residual renal volume
- Renal parenchymal volume taken up by small cysts (<5 mm3)
Additional functional parameters will be compared in the two groups at baseline and at 1, 2, 3 years follow-up as follows:
- Systolic and diastolic blood pressure
- GFR (plasma iohexol clearance)
- GFR (over baseline)
- RPF (plasma PAH clearance)
- Serum creatinine concentration
- Diuresis
- 24 h urinary protein excretion rate
- 24 h urinary albumin excretion rate
- Protein, albumin, creatinine concentrations on spot morning urine samples
- Protein /creatinine ratio on spot morning urine samples
- Albumin/creatinine ratio on spot morning urine samples
- Urinary sodium, urea, glucose, phosphorus concentrations (24 hr samples)
- Urine osmolality (calculated)
- Correlation analyses between MRI and functional parameters will be also performed
Patients Patients enrolled in this long-term follow-up study are those with ADPKD and normal renal function or mild to moderate renal insufficiency (estimated GFR >40 ml/min/1.73 m2 by MDRD equation), no evidence of associated systemic, renal parenchymal or urinary tract disease and no specific contraindication to the study drug.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bergamo, Italy, 24128
- Hospital "Ospedali Riuniti" Unit of Nephrology and Dialysis
-
Lecce, Italy
- Hospital "V. Fazzi" - Unit of neprology and Dialysis
-
Milan, Italy
- Hospital "Presidio Osp. Maggiore Policlinico"
-
Napoli, Italy
- University "Federico II" of Naples
-
Treviso, Italy
- Hospital Cà Foncello
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age>18 years
- Clinical and ultrasound diagnosis of ADPKD
- GFR >40 ml/min/1-73 m2 (estimated by the 4 variable MDRD equation)
- Written informed consent
Exclusion Criteria
- Diabetes
- Overt proteinuria (urinary protein excretion rate >1g/24 hours) or abnormal urinalysis suggestive of concomitant, clinically significant glomerular disease
- Urinary tract lithiasis, infection or obstruction
- Cancer
- Psychiatric disorders and any condition that might prevent full comprehension of the purposes and risks of the study
- Pregnancy, lactation or child bearing potential and ineffective contraception (estrogen therapy in post menopausal women should not be stopped)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Saline solution
|
Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
|
Experimental: somatostatin
|
Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change over baseline of the total kidney volume at 1 and 3 years follow-up (estimated by gadolinium contrast enhanced and T2-weighted magnetic resonance imaging, MRI).
Time Frame: Basal, 1 and 3 years follow-up
|
Basal, 1 and 3 years follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute and percent change over baseline by MRI analysis will be compared in the two ADPKD groups at baseline, at one and three years follow-up of:
Time Frame: Basal, 1 and 3 years follow-up
|
Basal, 1 and 3 years follow-up
|
Total renal parenchymal volume
Time Frame: Basal, 1 and 3 years follow-up
|
Basal, 1 and 3 years follow-up
|
Residual renal volume
Time Frame: Basal, 1 and 3 years follow-up
|
Basal, 1 and 3 years follow-up
|
Renal parenchymal volume taken up by small cysts, minor of five mmcubic
Time Frame: Basal, 1 and 3 years follow-up
|
Basal, 1 and 3 years follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Norberto Perico, MD, Mario Negri Institute for Pharmacological Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Kidney Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Somatostatin
Other Study ID Numbers
- ALADIN
- 2005-005552-41 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
University of North Carolina, Chapel HillNational Institute of General Medical Sciences (NIGMS)CompletedRenal Disease | Autosomal Dominant Polycystic Kidney Disease | ADPKDUnited States
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Assistance Publique - Hôpitaux de ParisIPSEN pharmaceutical company, Boulogne-Billancourt, FranceCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKDFrance
-
University Medical Center GroningenRadboud University Medical Center; Erasmus Medical Center; Leiden University...UnknownAutosomal Dominant Polycystic Kidney Disease (ADPKD)Netherlands
-
Palladio BiosciencesCentessa Pharmaceuticals plcTerminatedADPKD | Polycystic Kidney Disease, AdultUnited States
-
Children's National Research InstituteRecruiting
-
Tufts Medical CenterCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Vertex Pharmaceuticals IncorporatedNot yet recruitingAutosomal Dominant Polycystic Kidney Disease (ADPKD)
-
University of CologneRecruitingADPKD (Autosomal Dominant Polycystic Kidney Disease)Germany
-
University of ZurichCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Switzerland
Clinical Trials on Long-acting somatostatin
-
IpsenTerminatedMalignant Carcinoid SyndromeUnited States
-
Intra-Cellular Therapies, Inc.CompletedSchizophreniaUnited States
-
Mayo ClinicCompletedCirrhosis | Portal Hypertension | Esophageal Varices
-
Koneksa HealthCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)Childhood Asthma Research and Education NetworkCompletedLung Diseases | Asthma
-
National Taiwan University HospitalCompletedDiabetes Mellitus | Diabetic Retinopathy | Vitreous HemorrhageTaiwan
-
Oregon Health and Science UniversityBayer; Merck Sharp & Dohme LLC; Society of Family PlanningTerminated
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIV-1-infectionUnited States, Brazil, South Africa, Uganda, Botswana, Thailand
-
Boehringer IngelheimCompleted
-
Emory UniversityCompletedDiabetes Mellitus | Type 1 DiabetesUnited States